Boehringer Ingelheim
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Germany · 10K+ Employees
View Company Info for Free
Overview
Headquarters
Binger Strasse 173, Ingelheim am Rhein, ...Phone Number
+49 6132770Website
www.boehringer-ingelheim.comRevenue
$31.4 BillionIndustry
ZI Rank: 2
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
25
1
3
3
3
2
About Boehringer Ingelheim
Boehringer Ingelheim is a privately held, research-driven pharmaceutical company headquartered in Ingelheim am Rhein, Germany, founded in 1885. The company researches, develops, and manufactures prescription medicines and healthcare products across three core business areas: Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. Its primary therapeutic focus areas include respiratory diseases, oncology, immunology, cardiometabolic conditions, and central nervous system disorders. Boehringer Ingelheim also develops and manufactures veterinary products for companion animals, livestock, and poultry. Operating in over 100 countries with more than 53,000 employees globally, the company maintains a broad network of research, manufacturing, and commercial sites across Europe, North America, and Asia. It is one of the largest privately owned pharmaceutical companies in the world.Explore more
Boehringer Ingelheim Org Chart
JO
Global Executive Vice President, Finance and ...
TD
Group Functions Controller
TS
Senior Human Pharma BU Commercial Controller ...
MM
Human Pharma Lead, Msi At Boehringer Ingelhei...
FB
Human Pharma Sagea Controller (, Gulf & Afric...
AC
Biopharmaceuticals Finance Controller
ES
HP Commercial Controller
JA
Controller Human Pharma Ecuador and Perú
ÖT
Regional Business & Africa Finance Controller
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Boehringer Ingelheim your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Boehringer Ingelheim is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Boehringer Ingelheim launches new products
Website visits: Recent activity has been detected on your website
Click to see if Boehringer Ingelheim had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Boehringer Ingelheim
Boehringer Ingelheim, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Boehringer Ingelheim has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Boehringer Ingelheim recently announced quarterly report
Funding: Get notified immidiatlly once Boehringer Ingelheim has new funding data
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Company Profile Activity
Activity Insights
Boehringer Ingelheim is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Boehringer Ingelheim is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Boehringer Ingelheim.
Boehringer Ingelheim financials insights
Gather financial insights about Boehringer Ingelheim, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2017
Other Financing Round
$217M
Boehringer Ingelheim Tech Stack
A closer look at the technologies used by Boehringer Ingelheim
Most Recent Scoops
Open Position
Person-Based
Contracts
Person-Based
Partnership, Medical Research, Pharmaceuticals
Open Position
Open Position
Boehringer Ingelheim News & Media
Boehringer Ingelheim strengthens obesity pipeline as potential first-in-class triple receptor agonist BI 3034701 enters Phase II development
Ingelheim, Germany – Boehringer Ingelheim today announces the start of a Phase II clinical trial evaluating its investigational triple GLP-1/GIP/NPY2 receptor agonist, BI 3034701, in patients with obesity and overweight.1 The trial represents a significant milestone for Boehringer’s cardiometabolic and obesity pipeline, which aims to address obesity as a central driver of interconnected cardiovascular, renal and metabolic conditions.5,6Boehringer Ingelheim reports first-half 2026 sales growth, driven by JARDIANCE® and new product launches in the U.S.
Boehringer Ingelheim reported continued sales growth in the first half of 2026, driven by strong growth in the U.S. due to increased demand for JARDIANCE® (empagliflozin) and successful new launches. Group net sales increased by 16.2%* to EUR 15.8 billion, with Human Pharma contributing EUR 13.1 billion and Animal Health EUR 2.6 billion.Boehringer Ingelheim accelerates precision oncology research with initiation of three Phase III trials in hard-to-treat cancers
Ingelheim, Germany and Ridgefield, Conn - Boehringer Ingelheim is advancing biomarker-informed approaches and extending precision care across multiple cancers and stages of disease, reinforcing its ambition to bring unprecedented impact and improve long-term outcomes where unmet need remains high.4,5,6 The company has initiated two Phase III clinical trials within the DAREON® program: DAREON®-Lung-1 in small cell lung cancer (SCLC) and DAREON®-NEC-1 in extrapulmonary neuroendocrine carcinoma (epNew analyses from FIBRONEER™ trials suggest survival benefit with nerandomilast in IPF and PPF
Not intended for UK and US audiences
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Frequently Asked Questions Regarding Boehringer Ingelheim
Sign Up For FreeTo access detailed company insights
Boehringer Ingelheim is a privately held, research-driven pharmaceutical company headquartered in Ingelheim am Rhein, Germany, founded in 1885. The company researches, develops, and manufactures prescription medicines and healthcare products across three core business areas: Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing.... Read More
